

# Traverse Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/T6AB55A07A24EN.html>

Date: January 2021

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: T6AB55A07A24EN

## Abstracts

Traverse Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires and markets drugs for the treatment of rare diseases. The company's products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin's pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Travere Therapeutics is headquartered in San Diego, California, the US.

### Travere Therapeutics Inc Key Recent Developments

Nov 16,2020: Retrophin announces corporate name change to Travere Therapeutics

Jul 30,2020: Retrophin reports second quarter 2020 financial results

May 11,2020: Retrophin reports first quarter 2020 financial results

Apr 09,2020: Retrophin appoints Suzanne L. Bruhn, Ph.D. to Board of Directors

Mar 10,2020: Ligand's presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com

**Key benefits of buying this profile include:**

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

## Contents

Table of Contents

List of Tables

List of Figures

### **SECTION 1 - ABOUT THE COMPANY**

Travere Therapeutics Inc - Key Facts

Travere Therapeutics Inc - Key Employees

Travere Therapeutics Inc - Key Employee Biographies

Travere Therapeutics Inc - Major Products and Services

Travere Therapeutics Inc - History

Travere Therapeutics Inc - Company Statement

Travere Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview

Travere Therapeutics Inc - Business Description

Product Category: Bile Acid Products

Overview

Performance

Product Category: Thiola

Overview

Performance

R&D Overview

Travere Therapeutics Inc - Corporate Strategy

Travere Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Travere Therapeutics Inc - Strengths

Travere Therapeutics Inc - Weaknesses

Travere Therapeutics Inc - Opportunities

Travere Therapeutics Inc - Threats

Travere Therapeutics Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

*Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review*

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Travere Therapeutics Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Nov 16, 2020: Retrophin announces corporate name change to Travere Therapeutics

Jul 30, 2020: Retrophin reports second quarter 2020 financial results

May 11, 2020: Retrophin reports first quarter 2020 financial results

Apr 09, 2020: Retrophin appoints Suzanne L. Bruhn, Ph.D. to Board of Directors

Mar 10, 2020: Ligand’s presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com

Feb 28, 2020: Retrophin recognizes Rare Disease Day 2020 and the importance of working together toward more equitable access to care

Feb 24, 2020: Retrophin reports fourth quarter and full year 2019 financial results

Jan 13, 2020: Retrophin provides corporate update and 2020 outlook

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Travere Therapeutics Inc, Key Facts  
Travere Therapeutics Inc, Key Employees  
Travere Therapeutics Inc, Key Employee Biographies  
Travere Therapeutics Inc, Major Products and Services  
Travere Therapeutics Inc, History  
Travere Therapeutics Inc, Other Locations  
Travere Therapeutics Inc, Subsidiaries  
Travere Therapeutics Inc, Key Competitors  
Travere Therapeutics Inc, Ratios based on current share price  
Travere Therapeutics Inc, Annual Ratios  
Travere Therapeutics Inc, Annual Ratios (Cont...1)  
Travere Therapeutics Inc, Annual Ratios (Cont...2)  
Travere Therapeutics Inc, Interim Ratios  
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Travere Therapeutics Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Travere Therapeutics Inc, Performance Chart (2015 - 2019)

Travere Therapeutics Inc, Ratio Charts

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

### COMPANIES MENTIONED

AbbVie Inc

Albireo Pharma Inc

CoA Therapeutics Inc

Intercept Pharmaceuticals Inc

Lannett Co Inc

Pharmesis International Ltd

SciClone Pharmaceuticals Holding Ltd

TM3 Therapeutics BV

Voyager Therapeutics Inc



## I would like to order

Product name: Travers Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/T6AB55A07A24EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T6AB55A07A24EN.html>